We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
-10.91%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$157M
(-13%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
12.82%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
41
New
5
Increased
4
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$62.6M |
| 2 |
Tango Therapeutics
TNGX
|
+$49.8M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$38.6M |
| 4 |
EyePoint Inc
EYPT
|
+$24.7M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$20.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$56.4M |
| 2 |
Keros Therapeutics
KROS
|
+$17.1M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$7.62M |
| 4 |
AN2 Therapeutics
ANTX
|
+$1.66M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$1.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMPS
26
Compass Pathways
CMPS
$1.52B
| $14.6M | 1.43% |
3,858,000
| – | – |
|
27
Kura Oncology
KURA
$901M
| $12.4M | 1.21% |
1,423,642
| – | – |
|
|
MBX
28
MBX Biosciences
MBX
$2.92B
| $12M | 1.17% |
650,000
| – | – |
|
29
Kodiak Sciences
KOD
$2.62B
| $11.4M | 1.11% |
1,145,538
+137,380
| +14% | +$790K |
|
30
Entrada Therapeutics
TRDA
$236M
| $10.1M | 0.99% |
584,955
| – | – |
|
|
31
Keros Therapeutics
KROS
$202M
| $8.71M | 0.85% |
550,000
-329,344
| -37% | -$17.1M |
|
|
ADVM
32
DELISTED
Adverum Biotechnologies
ADVM
| $8.39M | 0.82% |
1,796,482
-211,857
| -11% | -$1.43M |
|
33
VistaGen Therapeutics
VTGN
$9.45M
| $7.9M | 0.77% |
2,676,580
| – | – |
|
|
JBIO
34
Jade Biosciences
JBIO
$1.21B
| $5.94M | 0.58% |
64,023
| – | – |
|
35
Nektar Therapeutics
NKTR
$2.41B
| $3.72M | 0.36% |
266,667
| – | – |
|
36
Avalo Therapeutics
AVTX
$1.03B
| $3.59M | 0.35% |
483,000
| – | – |
|
|
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
| $692K | 0.07% |
316,195
| – | – |
|
38
Cabaletta Bio
CABA
$444M
| $197K | 0.02% |
86,795
| – | – |
|
|
39
AN2 Therapeutics
ANTX
$178M
| – | – |
-1,555,118
| Closed | -$1.66M |
|
|
40
Edgewise Therapeutics
EWTX
$4.48B
| – | – |
-2,112,984
| Closed | -$56.4M |
|
|
41
Tarsus Pharmaceuticals
TARS
$2.62B
| – | – |
-231,820
| Closed | -$7.62M |
|
Similar funds
DILIC
KCM
ACM
BCP
ACA
MSC
TH
PMG
TCG Crossover Management's Q4 2024 Portfolio in Review
As of Q4 2024, TCG Crossover Management held 41 positions worth $1.02B, down 13% from $1.18B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
TCG Crossover Management deployed $131M of net new capital in Q4 2024, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Upstream Bio Inc: 2,801,763 shares worth $44.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Keros Therapeutics, an estimated $17.1M trimmed.
- TCG Crossover Management's largest Q4 2024 buy was Upstream Bio Inc: 2,801,763 shares worth $44.9M.
- TCG Crossover Management added most to EyePoint Inc in Q4 2024, an estimated $24.7M increase.
- TCG Crossover Management's biggest Q4 2024 reduction was Keros Therapeutics, cutting an estimated $17.1M.
- TCG Crossover Management fully exited Edgewise Therapeutics in Q4 2024, selling an estimated $56.4M.
- TCG Crossover Management's ten largest holdings make up 52% of its $1.02B portfolio in Q4 2024.
- TCG Crossover Management opened 5 new positions and closed 3 in Q4 2024.
- TCG Crossover Management's portfolio value fell 13% quarter-over-quarter to $1.02B.
Based on TCG Crossover Management's 13F filing for Q4 2024, filed 14 Feb 2025.